HCM Medical

HCM Medical, founded in 2019 and based in Amsterdam, established itself as a specialized CMO for regenerative biologics and advanced biomaterials before its acquisition by LifeNet Health in August 2025. Its core expertise lies in the ISO/GMP-compliant processing of tissues into medical products using technologies such as supercritical CO2 extraction, freeze-drying, and collagen purification. The acquisition by LifeNet Health strategically expands global manufacturing capacity to meet rising demand for regenerative therapies, integrating HCM's xenograft platform and antibiotic-coated implant technologies into a larger portfolio.

Specialized contract manufacturing platform for biologics and biomaterials, featuring supercritical CO2 (scCO2) processing for extraction/purification/sterilization, freeze-drying, collagen isolation/purification, aseptic cleanroom production, a closed-herd xenograft platform, and antibiotic-coated implant technologies.

HCM competes in the niche CMO segment for complex biologics and tissue-based products. Differentiators include its scCO2 technology and xenograft platform. Post-acquisition, its primary competitors are other large, integrated tissue processing and regenerative medicine companies, as well as traditional biopharma CMOs expanding into advanced therapies.